Edition:
United States

Shanghai Pharmaceuticals Holding Co Ltd (601607.SS)

601607.SS on Shanghai Stock Exchange

27.34CNY
23 Jun 2017
Change (% chg)

¥0.41 (+1.52%)
Prev Close
¥26.93
Open
¥26.58
Day's High
¥27.46
Day's Low
¥26.52
Volume
11,564,661
Avg. Vol
10,919,643
52-wk High
¥27.46
52-wk Low
¥17.20

Latest Key Developments (Source: Significant Developments)

Shanghai Pharmaceuticals Holding updates on capital increase agreement
Thursday, 15 Jun 2017 09:45am EDT 

June 15 (Reuters) - Shanghai Pharmaceuticals Holding Co Ltd <601607.SS>:Entered into a commercial factoring services framework agreement with shangshi factoring.Entered into a capital increase agreement with Shanghai Shentong Metro, Shangshi Leasing And Shangshi Commercial Factoring.Shentong Metro, Shangshi Leasing & Shangshi Factoring agree that co will contribute rmb137.5 million to capital of shangshi factoring.  Full Article

Shanghai Pharmaceuticals clarifies on reports about co's possible bid for Stada Arzneimittel AG
Tuesday, 16 May 2017 08:44pm EDT 

May 17 (Reuters) - Shanghai Pharmaceuticals Holding Co Ltd <601607.SS>:Recently discussed about possibilities of project Stada with a couple of financial investors.Bidding price of 70 euro per share that media mentioned is inconsistent with reality.Refers to reports that co is considering to team up on a bid for German pharmaceutical company, Stada Arzneimittel AG.  Full Article

Advent, Shanghai Pharma said to consider rival bid of about 70 euros a share for Stada - Bloomberg, citing sources
Monday, 15 May 2017 01:40pm EDT 

May 15 (Reuters) - :Advent, Shanghai Pharma said to consider rival bid of about 70 euros a share for Stada - Bloomberg, citing sources.  Full Article

Shanghai Pharmaceuticals posts qtrly net profit of RMB 999.4 mln
Thursday, 27 Apr 2017 06:15am EDT 

April 27 (Reuters) - Shanghai Pharmaceuticals Holding Co Ltd <601607.SS>:Qtrly net profit attributable RMB 999.4 million versus RMB 889.4 million.Qtrly revenue RMB 33.13 billion versus RMB 29.28 billion.  Full Article

Shanghai Pharmaceuticals Holding receives GMP certificate
Wednesday, 22 Mar 2017 10:23pm EDT 

Shanghai Pharmaceuticals Holding Co Ltd <601607.SS> : Says its unit received goods manufacture practice (GMP) certificate from Jiangsu Food and Drug Administration .Says certificate issued to perindopril tert-butylamine manufactured by the company and the valid period is until March 19, 2022.  Full Article

Shanghai Pharmaceuticals to apply to issue debentures worth up to 7 bln yuan
Wednesday, 22 Mar 2017 05:34am EDT 

Shanghai Pharmaceuticals Holding Co Ltd <601607.SS> : Says it will apply to issue debenture worth up to 7 billion yuan .Says proceeds will be used for loan repayment and supplement of working capital.  Full Article

Shanghai Pharmaceuticals to pay FY 2016 annual div as 3.60 yuan/10 shares
Wednesday, 22 Mar 2017 05:23am EDT 

Shanghai Pharmaceuticals Holding Co Ltd <601607.SS> :Says it will pay annual cash dividend as 3.60 yuan(pre-tax)/10 shares to shareholders for FY 2016.  Full Article

Shanghai Pharmaceuticals' 2016 net profit up 11.1 pct
Tuesday, 21 Mar 2017 07:30am EDT 

Shanghai Pharmaceuticals Holding Co Ltd <601607.SS><2607.HK> :Says 2016 net profit up 11.1 percent y/y at 3.2 billion yuan ($464.71 million).  Full Article

Shanghai Pharmaceuticals Holding unit receives GMP certificate
Monday, 20 Feb 2017 01:53am EST 

Shanghai Pharmaceuticals Holding Co Ltd <601607.SS> : Says co's controlling bio-pharmaceuticals unit receives GMP certificate from Shanghai Food and Drug Administration .Certificate is issued to plants of APIs (paclitaxel and docetaxel) in the unit and the valid period is until Jan. 21, 2022.  Full Article

Shanghai Pharmaceuticals updates on progress of participation in privatization of Vitaco
Wednesday, 30 Nov 2016 06:24am EST 

Shanghai Pharmaceuticals Holding Co Ltd <601607.SS> : On 30 November 2016, Vitaco has received approval of Vitaco's shareholders . Refers to announcements in relation to participation of SIIC Medical Science And Technology (Group) Limited in privatization of Vitaco Holdings .Transaction is still subject to approval of Federal Court of Australia.  Full Article

More From Around the Web